Aravive : Announces First Patient Dosed in Phase 2 Study of

Aravive Announces First Patient Dosed in Phase 2 Study


of Batiraxcept in Clear Cell Renal Cell Carcinoma


Preliminary top line data anticipated throughout 2022
... | January 31, 2022

Related Keywords

Houston , Texas , United States , Marek Ciszewski , Gail Mcintyre , European Commission , Drug Administration , Aravive Inc , Nasdaq , Aravive Announces First Patient Dosed , Clear Cell Renal , Chief Executive Officer , Fast Track , Fast Track Designation , Orphan Drug Designation , Investor Relations , Aravive , Nc Stock Exchange , News , Information , Press Release , Nnounces , First , Patient , Hosed , N , Hase , , F , Batiraxcept , Clear , Fell , Prenal , Reliminary , Top , Line , Data , Nticipated , Hroughout Arav Us03890d1081 ,